Australian sports tour company FanFirm has sued US sports merchandise giant Fanatics alleging ‘flagrant’ infringement of its trade marks.
Mineral exploration company Boart Longyear has been granted leave to appeal a finding that it infringed a patent for a mining tool, but it can’t avoid a recall of its tools, with a judge saying its actions were “not uninformed or innocent”.
Bookmaker Sportsbet has defeated a bid to overturn a freezing order against the owner of the sportsbet.com domain name in a trade mark infringement dispute stemming from a promotion agreement.
The operator of the Royal Perth Hospital has brought legal action against Griffith Hack alleging the law firm contributed to the “dishonest and fraudulent design” of a leading researcher to transfer the intellectual property rights to a stem cell manufacturing method developed inhouse.
Eco-conscious Australian skincare company Sukin has been hit with a lawsuit alleging it misled consumers by selling products labelled with a carbon neutral certification it did not hold.
Titan DMS, which provides software to car dealers across Australia, has expanded cross claims in a legal dispute with leading competitor Pentana Solutions, alleging the rival engaged in misuse of market power by threatening dealers who want to switch providers.
Novartis and and generic drug maker Pharmacor have resolved litigation over the Swiss pharmaceutical giant’s patents for blockbuster MS drug Gilenya.
The High Court will not wade into the global debate over whether artificial intelligence inventions should receive patent protection, letting stand a Full Court judgment that overturned a landmark victory for AI pioneer Dr Stephen Thaler.
Media company The Economist has failed in its opposition to registration of a trade mark for The Beer Economist, with an IP Australia delegate saying the mark was not substantially identical or deceptively similar to the UK publisher’s brand.
Infant formula maker Care A2 Plus has launched an attack on A2 Milk, filing a lawsuit arguing the dairy giant’s trade marks should be cancelled because they’re too generic and are being used to sell products that don’t exclusively contain the a2 protein.